GlassScriptPhysician profile
Matthew T Woods
NPI 1437276276
$16,589.34
in general payments reported to CMS, 2019-2025
38 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,742 · 2020: $1,891 · 2021: $1,390 · 2022: $2,057 · 2023: $2,173 · 2024: $2,710 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,509.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,296.62 | 2019-2025 | |
| Abbvie INC. | $1,975.40 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,452.97 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,226.83 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,129.62 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $809.37 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $666.35 | 2019-2025 | Adbry |
| Incyte Corporation | $557.97 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $511.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $430.01 | 2019-2025 | Aklief, Nemluvio |
| Amgen INC. | $420.74 | 2019-2025 | Otezla, Otezla |
| Merz North America, INC. | $415.45 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $387.08 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $345.51 | 2019-2024 | Targretin, Siliq, Jublia |
| Genzyme Corporation | $275.81 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $267.02 | 2023-2025 | Sotyktu |
| Ucb, INC. | $231.96 | 2019-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $212.00 | 2020-2021 | |
| Almirall LLC | $141.23 | 2019-2025 | Klisyri |
| Epi Health, LLC | $102.86 | 2019-2022 | |
| Biofrontera INC. | $101.54 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $88.17 | 2019-2025 | |
| Dusa Pharmaceuticals, INC. | $69.99 | 2019 | |
| Kyowa Kirin, INC. | $57.83 | 2020-2024 | Poteligeo |
| Allergan, INC. | $54.25 | 2019 | |
| Encore Dermatology INC. | $49.49 | 2019-2020 | |
| Dermavant Sciences, INC. | $44.82 | 2023 | Vtama |
| Celgene Corporation | $44.54 | 2019 | |
| Prugen, INC. Pharmaceuticals | $44.07 | 2019 | |
| Journey Medical Corporation | $30.54 | 2019 | |
| Promius Pharma LLC | $28.86 | 2019 | |
| Organon LLC | $28.71 | 2025 | Vtama, Nexplanon |
| Krystal Biotech INC | $19.05 | 2024 | Vyjuvek |
| Botanix Sb INC | $17.74 | 2025 | Sofdra |
| Stemline Therapeutics INC. | $17.64 | 2021 | |
| Dermira, INC. | $12.56 | 2019 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 | |
| Nabriva Therapeutics, Plc | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.